IRON (Disc Medicine) Interest Coverage : 0 (At Loss) (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Disc Medicine Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Disc Medicine's Operating Income for the three months ended in Mar. 2025 was $-39.95 Mil. Disc Medicine's Interest Expense for the three months ended in Mar. 2025 was $-0.90 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Disc Medicine's Interest Coverage or its related term are showing as below:

IRON's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 125.165
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Disc Medicine Interest Coverage Historical Data

The historical data trend for Disc Medicine's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Disc Medicine Interest Coverage Chart

Disc Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Coverage

N/A

Disc Medicine Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Coverage	Get a 7-Day Free Trial															N/A	N/A	N/A	-	-

Competitive Comparison of Disc Medicine's Interest Coverage

For the Biotechnology subindustry, Disc Medicine's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Disc Medicine's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Disc Medicine's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Disc Medicine's Interest Coverage falls into.

Save Embed

;

Save Embed

;

Disc Medicine Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Disc Medicine's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Disc Medicine's Interest Expense was $-0.57 Mil. Its Operating Income was $-129.72 Mil. And its Long-Term Debt & Capital Lease Obligation was $29.87 Mil.

Disc Medicine did not have earnings to cover the interest expense.

Disc Medicine's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Disc Medicine's Interest Expense was $-0.90 Mil. Its Operating Income was $-39.95 Mil. And its Long-Term Debt & Capital Lease Obligation was $30.16 Mil.

Disc Medicine did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Disc Medicine (NAS:IRON) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Disc Medicine Interest Coverage Related Terms

Thank you for viewing the detailed overview of Disc Medicine's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Disc Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Disc Medicine Inc (NAS:IRON) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472

Website

https://www.discmedicine.com

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Executives

William Jacob Savage	officer: Chief Medical Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Mona Ashiya	director, 10 percent owner	C/O SIERRA ONCOLOGY, INC., 2150 - 885 WEST GEORGIA STREET, VANCOUVER, BRITISH COLUMBIA Z4 V6C 3E8
Rahul Khara	officer: General Counsel	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Jonathan Yen-wen Yu	officer: Chief Business Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
John D Quisel	director, officer: Chief Executive Officer	128 SIDNEY STREET, CAMBRIDGE MA 02139
William Richard White	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Kevin Bitterman	director	C/O POLARIS VENTURE PARTNERS, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Atlas Venture Fund X, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Joanne Bryce	officer: Chief Financial Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Brian Richard Macdonald	officer: Chief Innovation Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Ai Dmi Llc	10 percent owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Atlas Venture Associates X, Llc	10 percent owner	400 TECH. SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund I, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139